![Petra Kaufmann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Petra Kaufmann
Hoofd Techniek/Wetenschap/O&O bij
OVID THERAPEUTICS INC.
Profiel
Petra Kaufmann is currently Chief Medical Officer at Ovid Therapeutics, Inc. since 2025.
Former positions include Chief Medical Officer at Affinia Therapeutics, Inc. from 2021 to 2024, SVP, Head-Clinical Development & Analytics at Novartis Gene Therapies, Inc. from 2020 to 2021, Director-Rare Diseases Research at National Institutes of Health from 2015 to 2018, and Chief Medical Officer at Vigil Neuroscience, Inc. Education includes a graduate degree from The Trustees of Columbia University in The City of New York and a doctorate from the University of Bonn.
Actieve functies van Petra Kaufmann
| Bedrijven | Functie | Begin |
|---|---|---|
| OVID THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 02-12-2025 |
Eerdere bekende functies van Petra Kaufmann
| Bedrijven | Functie | Einde |
|---|---|---|
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Hoofd Techniek/Wetenschap/O&O | 01-03-2024 |
| AVEXIS INC | Corporate Officer/Principal | 01-02-2021 |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Corporate Officer/Principal | 01-02-2018 |
| VIGIL NEUROSCIENCE, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Petra Kaufmann
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
51
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Ovid Therapeutics, Inc.
 Ovid Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides medicines to children and adults with neurological disorders | Health Technology |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
University of Bonn
 University of Bonn Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
Vigil Neuroscience, Inc.
 Vigil Neuroscience, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops therapeutics for neurodegenerative diseases | Health Technology |
